RxDoctor Payments Data

William Thompson, MD

Ophthalmology · Roanoke, VANPI 1023015476

Payments from drug & device makers

$8,530in general payments, 2019–2025

Across 277 payments — averaging $30.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Glaukos Corporation$1K
  • Ocular Therapeutix, Inc.$990
  • AbbVie$688
  • Bausch & Lomb Americas Inc.$641
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$588
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$8,43099%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,530 in reported general payments places this provider in the 85th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$1,130,065
Medicare patients
1,511
Services billed
13,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost66$36,748
Cyclosporine18$10,240
RhopressaNetarsudil Mesylate16$8,324
MoxifloxacinMoxifloxacin Hcl320$7,790
XiidraLifitegrast11$7,509
CombiganBrimonidine Tartrate/Timolol20$6,931
VyzultaLatanoprostene Bunod11$6,773
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol22$6,477
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat358$5,810
Latanoprost686$5,786
Travoprost29$5,284
Prednisolone Acetate129$4,476
Brimonidine Tartrate46$3,237
SimbrinzaBrinzolamide/Brimonidine Tart11$2,942
Timolol Maleate118$2,444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$688$43,67986 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$641$14,28322 claims
Aerie Pharmaceuticals, Inc.Rhopressa$127$8,32416 claims
AlconSimbrinza$1,939$2,94211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →